Novo Nordisk enters collaboration with Heartseed on cell-based treatment

Through the new agreement, Novo Nordisk gets exclusive rights to develop, produce and market Heartseed's HS-001 product for the treatment of cardiovascular diseases all over the world, excluding Japan.
Photo: Stine Tidsvilde
Photo: Stine Tidsvilde

Novo Nordisk and Heartseed have entered an exclusive global partnership and license agreement over the development, production and marketing of Heartseed's HS-001 to treat cardiovascular diseases, Novo Nordisk reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading